SPARQL
Query
Update
Search
Quick
Advanced
Co-occurrence
RelFinder
About
Sources
Admin
System Info
Repository Management
Search Configuration
Sources
18172279
Source:
http://linkedlifedata.com/resource/pubmed/id/18172279
Search
Subject
(
59
)
Predicate
Object
All
Download in:
JSON
RDF
N3/Turtle
N-Triples
Switch to
Custom View
Named Graph
All
UniProt
NCBIGene
DrugBank
ClinicalTrials
UMLS
PubMed
Mappings
MentionedEntities
Language
All
English
Español
Português
Français
Deutsch
Русский
日本語
Български
Inference
Explicit and implicit
Explicit only
Implicit only
Statements in which the resource exists as a subject.
Predicate
Object
rdf:type
pubmed:Citation
lifeskim:mentions
umls-concept:C0087111
,
umls-concept:C0332161
,
umls-concept:C0450442
,
umls-concept:C1521840
,
umls-concept:C2936626
pubmed:issue
1
pubmed:dateCreated
2008-1-3
pubmed:abstractText
Over the past 60 years, cytotoxic chemotherapy has targeted the cancer cell. Despite this, there have been few cancer cures. A new approach to cancer therapy is to target the multicellular biological entity of the tumor microenvironment.
pubmed:language
eng
pubmed:journal
http://linkedlifedata.com/resource/pubmed/journal/9502500
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Cyclophosphamide
,
http://linkedlifedata.com/resource/pubmed/chemical/Indoles
,
http://linkedlifedata.com/resource/pubmed/chemical/Pyrroles
,
http://linkedlifedata.com/resource/pubmed/chemical/Thalidomide
,
http://linkedlifedata.com/resource/pubmed/chemical/lenalidomide
,
http://linkedlifedata.com/resource/pubmed/chemical/sunitinib
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1078-0432
pubmed:author
pubmed-author:AlexanderH RichardHR3rd
,
pubmed-author:BlansfieldJoseph AJA
,
pubmed-author:CaragacianuDianaD
,
pubmed-author:LibuttiSteven KSK
,
pubmed-author:LorangDominiqueD
,
pubmed-author:MoritaShane YSY
,
pubmed-author:MullerGeorgeG
,
pubmed-author:RoyalRichard ERE
,
pubmed-author:SchaferPeterP
,
pubmed-author:StirlingDavidD
,
pubmed-author:TangreaMichael AMA
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
270-80
pubmed:meshHeading
pubmed-meshheading:18172279-Animals
,
pubmed-meshheading:18172279-Antineoplastic Combined Chemotherapy Protocols
,
pubmed-meshheading:18172279-Cell Line, Tumor
,
pubmed-meshheading:18172279-Cell Proliferation
,
pubmed-meshheading:18172279-Cyclophosphamide
,
pubmed-meshheading:18172279-Endothelial Cells
,
pubmed-meshheading:18172279-Female
,
pubmed-meshheading:18172279-Fluorescent Antibody Technique
,
pubmed-meshheading:18172279-Humans
,
pubmed-meshheading:18172279-Indoles
,
pubmed-meshheading:18172279-Mice
,
pubmed-meshheading:18172279-Neoplasms, Experimental
,
pubmed-meshheading:18172279-Neovascularization, Pathologic
,
pubmed-meshheading:18172279-Pyrroles
,
pubmed-meshheading:18172279-Rats
,
pubmed-meshheading:18172279-Thalidomide
,
pubmed-meshheading:18172279-Xenograft Model Antitumor Assays
pubmed:year
2008
pubmed:articleTitle
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy.
pubmed:affiliation
Tumor Angiogenesis Section, Surgery Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA. jblansfield1@geisinger.edu
pubmed:publicationType
Journal Article